Catalent Buys Cook Pharmica for $950M To Boost Biologics Business

Sep 19, 2017

Catalent will buy Cook Pharmica for $950 million in cash, giving the company access to Cook Pharmica’s Bloomington, Indiana facility that specializes in biologics-based drug development. Currently, biologics account for nearly 14 percent of Catalent’s consolidated revenue.

Catalent is expected to pay $750 million at deal closes in the second quarter of the 2018 fiscal year.

Last year, Cook Pharmica generated $179 million in revenue.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments